Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Catalyst Pharmaceuticals Inc (CPRX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Catalyst Pharmaceuticals's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
14.740 -0.360    -2.38%
- Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 750,823
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 14.730 - 15.220
Catalyst Pharmaceuticals 14.740 -0.360 -2.38%

NASDAQ:CPRX Financials

 
A brief overview of the NASDAQ:CPRX financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Catalyst Pharmaceutical over time.

Catalyst Pharmaceuticals, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 110.57 million compared to USD 60.76 million a year ago. Net income was USD 34.84 million compared to USD 25.47 million a year ago. Basic earnings per share from continuing operations was USD 0.33 compared to USD 0.24 a year ago. Diluted earnings per share from continuing operations was USD 0.31 compared to USD 0.22 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

CPRX Income Statement

Gross margin TTM 63.56%
Operating margin TTM 21.8%
Net Profit margin TTM 17.93%
Return on Investment TTM 20.21%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 110.57 102.69 99.58 85.37
Gross Profit 92.79 4.86 83.58 71.86
Operating Income 41.69 -37.19 46.7 35.61
Net Income 34.84 -30.76 37.76 29.57

CPRX Balance Sheet

Quick Ratio MRQ 2.51
Current Ratio MRQ 2.88
LT Debt to Equity MRQ -
Total Debt to Equity MRQ 0.92%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 470.11 413.21 443.9 407.23
Total Liabilities 82.23 64.66 68.6 73.57
Total Equity 387.88 348.55 375.29 333.66

CPRX Cash Flow Statement

Cash Flow/Share TTM 1.35
Revenue/Share TTM 3.74
Operating Cash Flow  73.17%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 55.65 45.13 30.75 12.07
Cash From Investing Activities -38.32 -92.82 0 -162.37
Cash From Financing Activities -0.665 -10.13 -0.214 0.149
Net Change in Cash 16.66 -57.82 30.54 -150.15
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CPRX Comments

Write your thoughts about Catalyst Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Ishtiaq Bokhari
Ishtiaq Bokhari Jan 11, 2024 10:48AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
the recent Morgan Stanley convention for the pharmaceutical in San Francisco CPR access proving to be liquidate company and is very well performing and it's way up and a good time to jump on the boat
Giuseppe Giannachi
Giuseppe Giannachi Jan 23, 2023 10:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Wow... what happened? Any news?
Timothy Murphy
Timothy Murphy Sep 24, 2022 4:57PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
we need a rally boys!
jatin par
jatin par Sep 15, 2022 1:53PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
why down today?
Timothy Murphy
Timothy Murphy Aug 13, 2022 4:42PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
great investment, lets hope for even better profits, ahead!
Feb 02, 2021 11:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This is the ultimate bull case no reckless gambling.. The best stock
Feb 02, 2021 11:58AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The best stock with unlimited upside and practically no downside.
Feb 01, 2021 11:48AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Best Stock in industry healthy robust balance sheet plenty of cash and highly profitable! soo cheap
Imtanis Farah
Imtanis Farah Jan 07, 2021 12:26PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-announces-strategic-plan-product
Santosh Gujar
Santosh Gujar Dec 22, 2020 12:07PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
next target 5.01
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email